Bellezza Alisha
Known title: President, Thermal Spec SolnsCIK: 0001848483
Associated companies
Transaction History
| CC | ▲ Buy | Option Exercise | 8,912 | $129K | 3/6/2023 | View on chart |
| CC | ▲ Buy | Option Exercise | 5,453 | $131K | 3/6/2023 | View on chart |
| CC | ▼ Sell | Open Market | 5,453 | $193K | 3/6/2023 | View on chart |
| CC | ▼ Sell | Open Market | 7,415 | $263K | 3/6/2023 | View on chart |
| CC | ▲ Buy | Option Exercise | 5,936 | $206K | 3/6/2023 | View on chart |
| CC | ▼ Sell | Open Market | 5,936 | $211K | 3/6/2023 | View on chart |
| CC | ▲ Buy | Option Exercise | 7,415 | $193K | 3/6/2023 | View on chart |
| CC | ▼ Sell | Open Market | 8,912 | $316K | 3/6/2023 | View on chart |
| CC | ▼ Sell | Tax Withholding | 943 | $34K | 3/2/2023 | View on chart |
| CC | ▼ Sell | Tax Withholding | 525 | $18K | 3/1/2023 | View on chart |
| CC | ▲ Buy | Grant | 5,919 | $0 | 3/1/2023 | View on chart |
| CC | ▼ Sell | Open Market | 8,912 | $361K | 5/5/2022 | View on chart |
| CC | ▲ Buy | Option Exercise | 5,453 | $131K | 5/5/2022 | View on chart |
| CC | ▼ Sell | Open Market | 5,453 | $221K | 5/5/2022 | View on chart |
| CC | ▲ Buy | Option Exercise | 8,912 | $129K | 5/5/2022 | View on chart |
| CC | ▼ Sell | Tax Withholding | 795 | $21K | 3/2/2022 | View on chart |
| CC | ▲ Buy | Grant | 2,117 | $0 | 3/1/2022 | View on chart |
| CC | ▲ Buy | Grant | 19,245 | $0 | 3/1/2022 | View on chart |
| CC | ▼ Sell | Tax Withholding | 984 | $26K | 3/1/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
Chemours Q2 Earnings Call and UBS Price Target Cut
Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.
Chemours Q2 Earnings Call and UBS Price Target Cut. Chemours released its Q2 2026 earnings call transcript, providing details on its financial performance. UBS kept a neutral stance but lowered its price target to $16, reflecting a more cautious view of the company's outlook. The new target sits below the current average analyst target of $18.22 and near the support level of $15.07, indicating a potential short‑term pressure on the stock.